An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

作者：Orkin Chloe^*; Wang Jianmin; Bergin Colm; Molina Jean Michel; Lazzarin Adriano; Cavassini Matthias; Esser Stefan; Gomez Sirvent Juan Luis; Pearce Helen

来源：Pharmacogenetics and Genomics, 2010, 20(5): 307-314.

DOI：10.1097/FPC.0b013e3283390666

• abacavir
• histocompatibility complex class I
• HLA-B*5701
• hypersensitivity
• prevalence
• pretreatment screening

Objectives HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results.
Methods Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), >= 18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods.
Results A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98%, with country-specific estimates ranging from 1.53 to 7.75%. HLA-B*5701 prevalence was highest in the self-reported white population (6.49%) and lowest in the black population (0.39%). Local laboratory results had a high specificity (99.9%) and sensitivity (99.2%) when compared with the central laboratory results.
Conclusion This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100% sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.

• 出版日期2010-5